Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by toinv261on Oct 08, 2016 10:10am

238 Views

Post# 25325306

Pfizer

Sure can't help but speculate about RVX and Pfizer none the less rvx-208 (apabetalone) and rosuvastatin which is patented from what I recall.

i.e. the fact that zen3694 is in trials with mCRPC patients and we are moving into the second phase with enzalutimide which was bought buy Pfizer for $14 billion as I recall. Any success on this one and RVX should gain visibility and credibility.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_medivation

Happy Thanksgiving.
Cheers
Toinv

Bullboard Posts

Changing Europe’s dependency on HREE from China